New research has revealed a confronting life-expectancy gap for people with intellectual disability in NSW, highlighting ...
Clinical Trials Arena on MSN
Ultragenyx’s gene therapy shows sustained improvements in MPS IIIA
There are currently no approved disease-modifying therapies for MPS IIIA.
Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. Simple habits can support healthy aging, and they don't ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results